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Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the best therapeutic options
to cure acute leukemia (AL). However, many patients have no human leukocyte antigen (HLA)-matched do-
nor. Recently, we developed a new method for HLA-mismatched/haploidentical transplantation without in
vitro T cell depletion (TCD). This method combined granulotyce-colony stimulating factor (G-CSF)-primed
bone marrow and peripheral blood with intensive immunosuppression. We analyzed the outcome of 250
consecutive patients with AL who underwent HLA-mismatched/haploidentical transplantation with 1-3 mis-
matched loci of HLA-A, B, and DR from family donors via our new transplant protocol. Two hundred forty-
nine patients achieved sustained, full donor chimerism. The incidence of grade 2-4 acute graft-versus-host
disease (aGVHD) was 45.8%, and that of grades 3 and 4 was 13.4%, which was not associated with the extent
of HLA disparity. The cumulative incidence of total chronic GVHD (cGVHD) was 53.9% and that of extensive
cGVHD was 22.6% in 217 evaluable patients. One hundred forty-one of the 250 patients survived free of
disease recurrence at a median of 1092 days (range: 442-2437 days) of follow-up. Seventeen patients received
DLI as a treatment for relapse after transplantation and 7 patients achieved leukemia-free survival (LFS). The
3-year probability of LFS for acute myelogenous leukemia (AML) was 70.7% and 55.9%, and for acute lym-
phoblastic leukemia (ALL) it was 59.7% and 24.8% in standard-risk and high-risk groups, respectively. Lower
LFS were associated with diagnosis of acute leukemia in the high-risk group (P5 .001, relative risk [RR], 95%
confidence interval [CI]: 2.94[1.535-5.631]) and the occurrence of aGVHD of grades 3 and 4 (P 5 .004).
HLA-mismatched/haploidentical HSCTwas feasible with unmanipulated blood and bone marrow harvest.
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Acute leukemia (AL) is a commonmalignant colonal
disease of hematopoietic stem cells. Despite recent
promising advances in its therapy, allogeneic hemato-
poietic stem cell transplantation (allo-HSCT) remains
one of the best therapeutic options to cure AL [1]. A hu-
man leukocyte antigen (HLA)-matched related donor is
the first choice for allo-HSCT; however, only 25% to
30% of eligible patients have a related donor with suit-
able or closely matchedHLA type. For patients without
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bone marrow or cord blood have often been used as the
source of stem cells for transplantation [2,3]. Unfortu-
nately, in the case of an unsuccessful donor search or
insufficient cord blood cells, this approach may not be
viable. The alternative is to obtain hematopoietic stem
cells from an HLA-mismatched/haploidential family
donor. However, this approach, particularly prior to
the end of the last decade, was associated with poor en-
graftment, a high risk of early death, and severe graft-
versus-host disease (GVHD) [4,5]. Although T cell
depletion (TCD) or CD341 cell selection in vitro over-
came the HLA barrier, it was challenged because of de-
layed immune reconstitution, that is, high rate of
infections, relapse of leukemia, and consequently, poor
survival [6,7].
Recently, we developed a new method for HLA-
mismatched/haploidentical transplantation without
in vitro TCD [8]. The method involves sequential, in
vivo modulation of T cell functions in the recipient
and donor, and adjustment of the dose of donor hema-
topoietic stem cells. The 4 elements in the GIAC257
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with recombinant granulocyte colony-stimulating fac-
tor (rhG-CSF); I, intensified immunologic suppres-
sion; A, antihuman thymocyte immunoglobulin
(ATG) for the prevention of GVHD; C, combination
of peripheral blood stem cell transplantation
(PBSCT), and bone marrow transplantation (BMT).
Using this protocol, promising results for HLA-mis-
matched allo-HSCT without in vitro TCD have
been achieved at our institute.
In this paper, we report the outcome of 250 consecu-
tive patientswithALwhounderwentHLA-mismatched/
haploidentical transplantation via our new transplant
protocol.
MATERIALS AND METHODS
Study Setting and Participants
BetweenNovember 16, 2001 andMay 9, 2007, 250
consecutive patients with AL underwent HLA-mis-
matched/haploidentical allo-HSCT at the Institute
of Hematology, Peking University. The outcome of
117 patients was reported in 2006 [8]; these patients
were followed up again in this study. We enrolled pa-
tients with AL suitable for allo-HSCT who did not
have HLA-identical related or unrelated donors or
a source of stem cells from cord blood. This study
was approved by the institutional review board of Pe-
king University, and written informed consent was ob-
tained from all patients and their donors. Patients with
any uncontrolled infections or severe liver, renal, lung,
or heart diseases were not eligible for HSCT. The
characteristics of the patients and donors are shown
in Table 1.
Stem Cell Harvest
Family donors were ranked on the basis of HLA
match, age (younger preferred), gender (same pre-
ferred), and health status (better preferred). To deter-
mine HLA-A and B status, low-resolution DNA
techniques were used. High-resolution techniques
were used for the evaluation of HLA-DRB1, DQB1,
DP, and C loci. Maternal and noninherited maternal
antigens (NIMA) donors were preferred in the initial
stage of study. However, there was no difference be-
tween those factors affecting the outcome of transplan-
tation. Hence, there was no preference in the
subsequent study.
Donors were treated with rhG-CSF (Filgrastim,
Kirin, Japan; 5 mg$kg21$day21) injected subcutane-
ously (s.c.) for 5-6 consecutive days from day –3. On
the 4th day (day 01) of mobilization, bonemarrow cells
were harvested for the target volumeof 10-12mL$kg21
of donor weight or the target mononuclear cell (MNC)
count of 2  108 to 4  108$kg21 of recipient weight.
The cell counts were measured in the operatingroom. On the fifth (day 02) of mobilization, PBSC
were collected with a COBE Blood Cell Separator
(Spectra LRS; COBE BCT Inc., Lakewood, CO) at
a rate of 80 mL$min21 from a total blood volume of
10-12 L. The target MNC from bone marrow and pe-
ripheral blood was 4 108 to 6 108$kg21 of recipient
weight. Another collection of PBSCs was needed on
day 03 if cells collected on the previous 2 days were in-
sufficient. The fresh and unmanipulated bone marrow
andPBSCswere infused into the recipient on the day of
their collection. In instances of major ABO blood
group incompatibility, red blood cells were removed
frombonemarrow cells by density gradient sedimenta-
tion with Hespan (B. Braun Medical Inc., Irvine, CA),
according to the manufacturer’s instructions. The
surface markers of the graft cells were determined by
multicolor staining using monoclonal antibodies
specific for CD341, CD31, CD41, and CD81 cells,
essentially as described by Liu et al. [9].
Table 1. Characteristics of Patients with Acute Leukemia
Receiving HLA-Mismatched/Haploidentical HSCT
Age (years) 25.1(2-56)
Gender
male 154
female 96
HLA-mismatched loci of A, B, and DR Case
1 40 (16%)
2 105 (42%)
3 105 (42%)
AML 108 (100%)
Standard risk 74 (68.5%)
CR1 67
CR2 7
High risk 34 (31.5%)
CR3/>CR3 11
NR 21
Ph+(CR+NR) 2
ALL 142 (100%)
Standard risk 87 (61.3%)
CR1 82
CR2 5
High risk 55 (38.7%)
CR3/>CR3 17
NR 19
Ph+(CR+NR) 19
Transplantation yearly
2001-2002 22
2003 42
2004 55
2005 57
2006 47
2007:01-04 27
Donor/recipient gender
female-male 85
female-female 63
male-male 72
male-female 30
Donor
Mother 108 (43.2%)
Father 47 (18.8%)
Child 15 (6.0%)
Sibling 77 (30.8%)
Uncle or aunt 3 (1.2%)
CR1 indicates the first complete remission; NR, nonremission; Ph+,
Philadelphia chromosome positive.
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As described previously [8], all patients were
treated with regimen A, which consisted of the follow-
ing: cytosine arabinoside (4 g$m22$day21, intrave-
nously) on days –10 and –9; busulfan (12 mg$kg21
p.o. in 12 doses) on days –8, –7, and –6; cyclophospha-
mide (1.8 g$m22$day21, intravenously) on days –5 and
–4; semustine (250 mg$m22, orally) on day –3, and
Thymoglobulin (rabbit ATG, Sangstat-Genzyme, 2.5
mg$kg21$day21 intravenously or porcine ATG, Wu-
han, China, 20mg$kg21$day21) through days –5 to –2.
GVHD Prophylaxis and Treatment
All transplant recipients received cyclosporine A
(CsA), mycophenolate mofetil (MMF), and short-
term methotrexate (MTX). The dosage of CsA was
2.5 mg$kg21$day21 intravenously from day –9 until
bowel function returned to normal. At that point, pa-
tients were switched to oral CsA. Every 12 hours, 0.5
g MMF was administered orally from day –9 to day
130 after transplantation; following this, the dose
was tapered to half until day 160 and discontinued
thereafter. Following transplantation, a dose of 15
mg$m22 of mehotrexate was administered intrave-
nously on day 11 and 10 mg$m22 on days 13, 16,
and 111. Whole-blood CsA concentration was moni-
tored weekly using the fluorescence polarization im-
munoassay technique, and the dosage was adjusted in
order to maintain a minimum blood concentration of
150-250 ng$mL21. In cases where there was no evi-
dence of GVHD by day 140 to approximately 150,
CsA dosage was reduced by 1/8 to approximately 1/
10 dose each month and was discontinued at around
9-10 months. In cases where GVHD occurred in any
organ, CsA was continued and adjusted to the blood
concentration mentioned above.
Acute GVHD (aGVHD) was treated with methyl-
prednisolone (0.5-1 mg$kg21$day21). GVHDmanife-
station only in the skin was treated with a combination
of methylprednisolone and MTX or with MTX alone
[10]. MTX was given intravenously on days 1, 3, and
7, then subsequently at intervals of 7 days in the case
of complete or partial response for a total of 6-8 doses.
The dosage was 5 mg if white blood cells were\2 
109/L or platetelets\50 109/L; otherwise the dosage
was 10 mg.When there was inadequate or no response
to the primary therapy of GVHD, 1 mg$kg21 of anti-
Tac monoclonal antibody (Daclizumab; Roche, Basel,
Switzerland) was administered intravenously on days 1,
4, and 8, and subsequently at intervals of 7 days for a to-
tal of 3 to 6 doses.
Evaluation and Monitoring of Engraftment,
Chimerism, and Minimal Residual Disease
Myeloid recovery was defined asmaintenance of an
absolute neutrophil count above 0.5  109$L21 for 3consecutive days after the neutrophil nadir. Chimerism
was determined by at least 2 of the following 3methods:
DNA-based HLA typing (for mismatched loci), poly-
merase chain reaction (PCR) DNA fingerprinting of
short tandem repeats, and chromosomal fluorescence
in situ hybridization (FISH) (for Y chromosome).
Full donor chimerismwas defined as no donor hemato-
poietic or lymphoid cells detected with either of the
abovemethods.MRDwasmonitoredwith flow cytom-
etry (FCM) or quantitative PCR for BCR/abl, the
Wilms tumor gene (WT1), or AML/ETO according
to themolecular genetics of leukemia before transplan-
tation. On days 130, 160, 190, 1180, and year 11,
13, and 15, chimerism and minimal residual disease
(MRD) were detected.
Modified Donor Lymphocyte Infusion (DLI)
Modified DLI consists of 2 components: infusion
of G-CSF-primed PBSCs instead of nonprimed donor
lymphocytes and short-term immunosuppressive
agents to preventGVHDafterDLI.Therapeuticmod-
ifiedDLIwas performed in 7 acutemyelogenous leuke-
mia (AML) and 10 acute lymphoblastic leukemia
(ALL) patients as a treatment for hematologic disease
recurrence after transplantation. Cells were from cryo-
preserved PBSCs collected on day 02 or day 03 from 11
donors and from newly mobilized PBSCs from the
other 6 donors. The median number of CD31 cells in-
fused was 2.09 (0.84-5.6) 108/kg. Except for the 5 pa-
tients in the initial stage of study, 12 patients received
CsA or a low dose of MTX for 2-4 weeks after DLI
to prevent GVHD [11]. The prophylactic DLI was ad-
ministered to 13 high-risk patients when they showed
evidence of partial recipient chimerism or MRD fol-
lowing withdrawal of immunosuppressants and the ab-
sence of acute GVHD [12]. Six of these patients were
diagnosed as high risk for AML and 7 were diagnosed
as high risk for ALL. The G-CSF-primed PBSCs
used for DLI were cryopreserved on day 02 or 03.
The median number of CD31 cells infused was 0.49
(0.2-1.4)  108/kg. All patients were treated with
short-term immunosuppressive agents for 2-4 weeks.
Infection Prevention and Supportive Care
All patients were hospitalized in rooms with high-
efficiency particle-arresting (HEPA) air filters for 4-5
weeks from day –10 to the time of neutrophil recovery.
They received antibiotic prophylaxis with oral Tri-
methoprim-sulfamethoxazole to prevent infection by
Pneumocystis carinii from day –10 to 190; Fluconazole
for Candida albicans from day –10 to 130; acyclovir
for herpes simplex virus and varicella zoster virus
from day 11 to the time of CsA discontinuation; Ci-
proflaxacin for intestinal decontamination. Ganciclo-
vir (5 mg$kg21) was administered intravenously twice
daily from days –10 to –2 for prophylaxis of
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itoredweekly forCMVDNA (real-time PCR) orCMV
pp65 antigenemia tests. Patients with CMV antigene-
mia were treated with either Ganciclovir or Foscarnet.
CMV-related interstitial pneumonia (IP) was defined
according to reported criteria [13]. Surveillance for
bacterial, fungal, and viral infections were based on
clinical requirements. All blood products were irradi-
ated with 2500 cGy before infusion. Patients received
red blood cell transfusions if their hemoglobin levels
were below 70 g$L21 or platelet transfusions if their
platelet levels dropped below 20  109$L21. G-CSF
(5 mg$kg21day21, s.c.) was administered to all recipi-
ents from day 6 after transplantation until myeloid re-
covery. Human immunoglobulin (400 mg$kg21) was
given intravenously on days 11, 111, 121, and 131.
Definition and Statistics
Patients with malignancies were categorized as
‘‘standard risk’’ if they were in the first or second com-
plete remission (CR1 or CR2) of AL without Ph chro-
mosome. Patients were stratified as ‘‘high risk’’ if they
were in more than CR2, in nonremission, and in CR1
or CR2 with t(9;22). The incidence and severity of
GVHD was defined based mainly on a consensus con-
ference onGVHDgrading, except formanifestation in
the gastrointestinal tract, which was scored according
to the International BoneMarrowTransplant Registry
(IBMTR) system [14,15]. Biopsies of involved organs
are routinely performed in the gastrointestinal tract
for differential diagnosis. In some cases of suspected
chronic GVHD (cGVHD) of the skin, a biopsy was
used to differentiate skin allergies or fungal or parasitic
infections. Time to GVHD was defined as the time
from allo-HSCT to the onset of any grade of
GVHD. Patients were evaluated for cGVHD if they
survived for at least 100 days afterHSCT.Hematologic
relapse of leukemia after transplantation was defined as
the recurrence of signs and syndromes of leukemia.
The first day of stem cell infusion was defined as ‘‘day
01,’’ and the second day of infusion was ‘‘day 02,’’ and
so on. Days before transplant was preceded by ‘‘–’’,
and days after the last stem cell infusion was preceded
by ‘‘1.’’ Values were adjusted for engraftment at time
of death if the patient had not undergone engraftment;
for GVHD, the values were adjusted for survival and
relapse at last follow-up. For all surviving patients,
the end point of the last follow-up was August 16,
2008. The factors analyzed in univariate analysis in-
cluded the age and gender of patients and donors, time
from diagnosis to transplant, year of transplantation,
risk group, extent of HLA disparity, the count of
MNC, CD31, and CD341 cells infused. Univariate
probabilities of developing aGVHD and cGVHD,
treatment-related mortality (TRM), and relapse
were calculated using cumulative incidence curves to ac-commodate corresponding competing risk. Distribu-
tions for time to overall survival (OS), and leukaemia-
free survival (LFS) were evaluated using Kaplan-Meier
analysis. Outcomes events considered in multivariate
analyses were TRM, relapse, and LFS. First, the test
indicated that the proportionality assumptions hold.
Thefinalmultivariatemodels were built using a forward
stepwise model selection approach. Each model con-
tained all significant risk factors in univariate analysis.
Statistical software packages (SPSS 13.0 and SAS)
were used for all analyses.
RESULTS
Engraftment
All donors tolerated the procedures, and no severe
side effects occurred during either bone marrow har-
vest or leukapheresis. In the initial stage of study, 16 pa-
tients were administered with porcine ATG. Two
hundred thirty-four patients were administered with
rabbit ATG thereafter. Therewas no difference related
to outcome of transplantation between these 2 groups.
The actual ratio of MNC of G-BM to PBSC harvested
was from2:1 to 1:2 in themajority of patients (Table 2).
Myeloid, platelet recovery and sustained, full donor
chimerism were achieved in 249 patients after trans-
plantation. The median time for myeloid recovery
was 12 days (range: 9-26 days) and 15 days (range:
8-151 days) for platelet recovery. There was no statisti-
cally significant association between the extent ofHLA
disparity and the time of engraftment.
Acute GVHD
Of the 250 patients, 86 (34.4%) had no aGVHD,
49 (19.6%) had grade 1, 89 (35.6%) had grade 2, 11
(4.4%) had grade 3, and 15 (6.0%) had grade 4. At
100 days after transplantation, the cumulative inci-
dence of aGVHD grades 2-4 was 45.8%, and that of
grades 3 and 4 was 13.4% (Figure 1). No risk factors
that might influence the incidence of GVHD grades
3 and 4 were found with univariate analyses. Acute
GVHD occurred in 23 (57.5%) of 40 patients with
HLA mismatch at 1 locus, 70 (66.7%) of 105 patients
with mismatch at 2 loci, and 71 (67.6%) of 105 patients
Table 2. Subtypes of Cells fromG-CSF-Primed BoneMarrow
and PBSC Infused for Patients with Acute Leukemia Receiving
HLA-Mismatched/Haploidentical HSCT
Cell Type BM PBSC Total
MNC (108/ kg) 3.7 (0.31-12.2) 4.9 (0.4-12.2) 7.9 (3.1-14.8)
CD34+ (106/ kg) 1.1 (0.09-8.2) 1.3 (0.1-5.9) 2.1 (0.3-14.2)
CD3+ (108/ kg) 0.2 (0.02-3.1) 1.6 (0.2-6.5) 2.4 (0.1-10.7)
CD4+ (108/ kg) 0.1 (0.2-0.6) 0.9 (0.1-3.4) 1.1 (0.07-4.2)
CD8+ (108/ kg) 0.1 (0.009-0.4) 0.8 (0.1-3.9) 0.7 (0.1-3.1)
CFU-GM (105/ kg) 2.9 (1.2-9.7) 3.7 (1.9-10.0) 5.6 (2.6-21.4)
CFU-GM indicates colony-forming unit granulomonocyte.
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were diagnosed in 5 (12.5%) patients with HLA mis-
match at 1 locus, 7 (6.7%) patients with mismatch at
2 loci, and 14 (13.3%) patients with mismatch at 3 loci.
Of the 15 patients who developed aGVHD grade
4, 8 died ofGVHD, 4 patients died of infection at ame-
dian of 335 (110-553) days after transplantation after
controlling for severe GVHD.The other 3 patients re-
covered and remained free of GVHD until their last
follow-up at 217, 941, and 958 days after transplanta-
tion. Of the 11 patients who suffered from aGVHD
grade 3, 4 died: 1 died of GVHD; 1 died of veno-occlu-
sive disease (VOD), and the remaining 2 died of infec-
tion at 132 and 157 days after transplantation after
controlling for GVHD. The other 7 recovered and
survived until the end of study for a median of 1808
(527-1866) days.
Chronic GVHD
Of the 217 patients who survived for over 100 days
after transplantation, 92 (42.4%) developed cGVHD.
Sixty-one (28.1%) of these showed limited cGVHD,
while 31 (14.3%) showed extensive cGVHD. At 3
years after transplantation, the cumulative incidence
of total cGVHD was 53.9% and that of extensive
cGVHD was 22.6% (Figure 2). Chronic GVHD was
diagnosed in 21 (52.3%) of 38 patients with HLA mis-
match at 1 locus, 36 (40.4%) of 89 patients with mis-
match at 2 loci, and 35 (38.9%) of 90 patients with
mismatch at 3 loci. The development of cGVHD
and extensive cGVHDwas not associated with the fac-
tors analyzed in univariate analyses. The patients who
developed aGVHD grade 2 to 4 had a higher risk of
developing extensive cGVHD than those without
aGVHD grade 2 to 4 (52.8% versus 26.6%, P5 .001).
Figure 1. Incidence of total aGVHD and severe aGVHD after HLA-
mismatched/haploidentical HSCT.Infection, Transplantation-Related Toxicity and
Immune Reconstitution
A total of 120 occurrences of opportunistic infec-
tions were recorded in 106 patients during the duration
of follow-up. Themedian time for an opportunistic in-
fection to developwas 280 days (range: 5-1120 days) af-
ter transplantation. The infected loci included lungs
(74 occurrences), skin (28 occurrences), gastrointesti-
nal tract (24 occurrences), and central nervous system
(6 occurrences). The skin infections were caused by
the varicella-zoster virus (16 cases) and herpes simplex
virus (12 cases). The pathogens found in pneumonia
were bacteria in 13 cases, Aspergillus in 18 cases, Can-
dida albicans in 1 case, Pneumocystis carinii in 5 cases,
andCMV in 16 cases.The other 21 cases of pneumonia
were negative for pathogens, and of these, 9 cases re-
sponded to antibiotics. At 3 years after transplantation,
the cumulative incidence of opportunistic infections
was 49.1%, without risk factors found in statistical
analyses.
The reconstitution of natural killer cells returned to
normal within 4 weeks after transplantation, as recently
reported [16]. At 3 months after HSCT, the peripheral
blood counts of CD41 T cells were 129.00 (24.88-
510.82$mL21. The median of CD81 cell counts at
160dayswas526.50 (4.54-2742.73)$mL21 and returned
to normal (median: 656.3$mL21; range: 50.92$mL21-
3708.04$mL21) within 90 days after transplantation.
Relapse
Of the 250 patients, 45 (AML, 13; ALL, 32) re-
lapsed after transplantation; of these, 22 (AML, 6;
ALL, 16) were from the high-risk group. The 3-year
probability of relapse in the standard-risk group was
11.9% and 24.3% for AML and ALL, respectively,
and that in high-risk group was 20.2% and 48.5%
Figure 2. Incidence of cGVHD and extensive cGVHD after HLA/mis-
matched/haploidentical HSCT.
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sis, diagnosis of acute leukemia in the high-risk group
was found to be an independent risk factor for relapse;
P 5 .002, relative risk [RR] (95% confidence interval
[CI]): 3.018 (1.494-6.097); Figure 3a and 3b. Of the
45 patients, 17 received therapeutic modified DLI; 7
of these patients achieved complete remission and
donor chimerism and survived at a median of 520
(300–1810) days after DLI. These 7 patients included
3 standard-risk group patients with ALL, 1 high-risk
group patient with ALL, and 3 standard-risk group
patients with AML.
LFS and TRM
Up to August 16, 2008, 148 patients (AML, 73; and
ALL, 75) were alive; 141 achieved LFS throughout
the follow-up of 1112 days (range: 442-2437 days).
Figure 3. (a) Relapse of patients with AML after HLA-mismatched/hap-
loidentical HSCT. (b) Relapse of patients with ALL after HLA-mis-
matched/haploidentical HSCT.However, the other 7 patients relapsed after transplan-
tation and received DLI; thereafter, all achieved LFS.
The 148 patients comprised 114 (AML, 54; ALL, 60)
standard-risk patients and 34 (AML, 19; ALL, 15)
high-risk patients. The 3-year probability of LFS for
AML was 70.7% and 55.9% and for ALL was 59.7%
and 24.8% in the standard-risk and high-risk groups,
respectively (Figrue 4a and 4b). Because 7 patients re-
lapsed after transplantation and achieved LFS follow-
ing therapeutic DLI, the OS was higher than LFS in
most groups; those were 72.5%, 55.9% for AML,
65.0%, and 26.5% for ALL in the standard-risk and
high-risk groups, respectively (Figure 5a and 5b).Thir-
teen patients received prophylactic DLI because of
their high risk of disease recurrence and 6 of them sur-
vived free of leukemia at a median of 1458 (532-1767)
days after transplantation. In term of predictors with
multivariate analysis, lower LFS was associated with
Figure 4. (a) LFS of patients with AML after HLA-mismatched/haploi-
dentical HSCT. (b) LFS of patients with ALL after HLA-mismatched/hap-
loidentical HSCT.
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.001, RR (95% CI): 2.94 (1.535-5.631). The signifi-
cance of influence of aGVHD grades 3 and 4 on LFS
was found in univariate analysis (P 5 .004), not in
multivariate analysis.
Totally, 102 (AML, 35; ALL, 67) out of the 250 pa-
tients died: 38 (37.3%) (AML, 11; ALL, 27) from recur-
rent leukemia and 64 (62.7%) (AML, 22; ALL, 42) from
transplant-related complications. The causes of trans-
plantation-related deaths included GVHD in 10 cases
(aGVHD, 9; and extensive cGVHD, 1), infection in 42
cases (lung, 29; central nervous system [CNS], 4; and in-
testinal, 9), organ failure in 3 cases, suicide in 1 case, dis-
continuation of treatment because of inability to meet
expenses in 4 cases, graft failure in 1 case, and posttrans-
plantation lymphoproliferative disorder (PTLD) in 3
Figure 5. (a) OS of patients with AML after HLA-mismatched/haploi-
dentical HSCT. (b) OS of patients with ALL after HLA-mismatched/hap-
loidentical HSCT.cases. The TRM on day 100 after transplantation in
the standard- and high-risk groups was 6.8% and
5.9% for AML and 6.9% and 25.9% for ALL, respec-
tively. At 3 years, the TRM in standard-risk and high-
risk groups was 19.4% and 29.4% for AML and
21.2% and 50.8% for ALL, respectively. In term of
predictors with multivariate analysis, higher TRM was
associatedwith diagnosis of ALL in the high-risk group;
P5 .049,RR (95%CI): 2.422 (1.005-5.835).The signif-
icance of influence of aGVHD grades 3 and 4 on TRM
was found in univariate analysis (P 5 0.000), not in
multivariate analysis.
DISCUSSION
Our study confirmed and extended our previous
finding that transplantation of G-CSF-primed bone
marrow (G-BM) and PBSCs from HLA-mismatched/
haploidentical related donors resulted in a high rate of
engraftment and a similar incidence of GVHD as that
observed in HLA-identical allo-HSCT [8,17]. Usu-
ally, it is believed that extensive TCD is essential for
the prevention of aGVHD in HLA-mismatched/hap-
loidentical HSCT. However, in this study, the T cell
number infused was 2.4 (0.1-10.7)  108$kg21. More-
over, the cumulative incidence of aGVHD of grades 3
and 4 at 100 days was only 13.4% (this was lower than
that observed in a previous report). The cumulative in-
cidence of cGVHD and extensive cGVHD at 2 years
after transplantation was only 53.9% and 22.6%,
respectively, which was not higher than that in HLA-
identical sibling donor transplantation [4,17,18].
There was no difference in the cumulative incidence
of aGVHD with HLA disparity; this was consistent
with our previous results. The rationale for using
G-CSF-primed bone marrow (G-BM) combined
with PBSC as a graft is 3-fold: (1) G-CSF primed
PBSC grafts do not cause higher aGVHD than mar-
row grafts [19]. Compared with PBSCT, the use of
G-BM resulted in comparable engraftment, reduced
severity of aGVHD, and less subsequent cGVHD
[20]. (2) The experimental data showed that the counts
of CD31, CD41, and CD81T cells were different be-
tween the mixture grafts and PBSC, steady-state BM,
or the G-BM [21]; (3) our recent study demonstrated
that the combination use of G-BM and PBSC in pro-
portions from 2:1 to 1:2 of MNC counts maintained
T cell hyporesponsiveness and polarization of T cells
fromTh1 to Th2, which would improve their immune
tolerance ability in a HLA-mismatched/haploidentical
transplant setting [22]. Our series of experimental and
clinical data confirmed the safety and feasibility of the
novel regimen, which overcame the HLA barrier with-
out in vitro TCD for HLA-mismatched/haploidenti-
cal HSCT. Compared with the data reported by
Beatty and Szydlo [23,24], the transplantation
264 Biol Blood Marrow Transplant 15:257-265, 2009X.-J. Huang et al.outcomes, such as survival and mortality, were better
in the present study. The reason for the improvement
might be because of the use of G-BM combined with
PBSC as a graft, use of ATG and other immunosup-
pressants, as well as better supportive care and training
of clinical staff in the past decade. However, the rate of
engraftment and incidence of aGVHD grade 3-4 were
better than those in previous reports, whichmight sug-
gest the advantage of this protocol in inducing immune
tolerance.
In the standard-risk group, the 3-year probability
of relapse for AML and ALL was similar, that is,,
14.8% and 15.4% respectively. Surprisingly, in AML,
the relapse rate is similar between standard- and
high-risk groups. This may be partially explained by
the application of prophylactic DLI, which might be
helpful in decreasing the relapse rates in high-risk
AMLpatients following transplantation [12]. Although
the prophylactic DLI resulted in a 20.7% incidence of
severe GVHD, death from aGVHD was very low be-
cause of the strategy of preemptive evaluation and the
prevention of and therapy for GVHD. Despite giving
prophylactic DLI, disease recurrence in the high-risk
ALL patients was 56.6%. The inclusion of patients
with advanced stage of disease in the present study
may have contributed to the high rate of relapse in
high-risk ALL. One-third of our patients (55 of 142)
presented with highly advanced refractory ALL, in-
cluding Philadelphia chromosome-positive (Ph1)
ALL. Further, 34.5% (19 of 55) were in the nonremis-
sion state, 30.9% (17 of 55).CR2 and only 7 patients
received prophylactic DLI. Moreover, this indicated
that even in HLA-mismatched HSCT, ALL such as
Ph1 ALL may be insensitive to DLI; thus, the risk of
leukemia relapse was still present, particularly in pa-
tients with high-risk ALL compared to those with
AML. In our study, the LFS in the standard-risk group
patients was 70.7% forAMLand55.9% forALL,while
the corresponding values reported by Ruggeri et al.
[18] were 60% for AML and 40% for ALL, respec-
tively.Moreover,weobtainedbetter results for patients
in the nonremission stage (59.7% for AML and 24.8%
for ALL) than previously reported (10% and 13%, re-
spectively) [18]. However, given the different patient
populations, and the nonrandomized comparison, the
results should be cautiously interpreted and compared.
Because of high levels of T cell infusion, the recon-
stitution ofTcells wasmuch faster in our study than the
slow rate of T cell recovery previously reported in T
cell depleted settings; this may have contributed to
the relatively lower percentage of nonleukemic deaths
[25,26]. Although CMV infection was higher (68%),
IP occurred in only 6.4% patients (unpublished data).
A previous study onHSCTwithATGconditioning re-
ported complications with a high rate of lymphoproli-
ferative disorders (LPD) related to the Epstein-Barr
virus [26]. In this study, the incidence of PTLD wasonly 0.12% (3 cases), probably because of a more rapid
immune reconstitution.
In conclusion, the overall results of our study in
terms of TRM and disease-free survival (DFS) showed
favorable outcomes compared with those expected for
patients at a similar stage of disease following haploi-
dentical transplantation with in vitro TCD [5]. The
high rate of engraftment, relatively lower incidence
of GVHD, and higher OS demonstrated that HLA-
mismatched/haploidentical HSCT was feasible with
unmanipulated blood and bone marrow harvest.
In the future, further reduction of relapse and other
complications will lead to improved clinical outcomes.
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